TSE:4523Pharmaceuticals
Eisai (TSE:4523) Could Be 15% Below Fair Value As Pipeline News Builds
Eisai (TSE:4523) has drawn fresh attention after the UK regulator accepted its insomnia drug lemborexant for review, along with new Alzheimer’s data plans and oncology filings that collectively spotlight its neurology and cancer pipeline.
See our latest analysis for Eisai.
Those updates on lemborexant, lecanemab and taletrectinib land against a share price of ¥4,340, with a 1 month share price return of 14.97% but a 3 year total shareholder return that is down 48.79%. This suggests short term...